Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 15 of 15 for “"Esomeprazole"”.
-
EVALUATING THE CHEMOTHERAPEUTIC EFFECTS OF SR9009 AND ESOMEPRAZOLE ON ORAL SQUAMOUS CELL CARCINOMA USING CIRCADIAN-TAILORED INNOVATIVE THERAPEUTIC APPROACHES
… a circadian clock regulating drug, and/or Esomeprazole, a proton pump inhibitor in HPV- (FaDu) and HPV+ (2A3) OSCC cell lines. To study the extent of disruption of circadian clock gene expression levels after Esomeprazole administration, we analysed the expression of clock genes, BMAL1 and …
-
AN IN VITRO INVESTIGATION INTO THE MECHANISM OF THE CLINICALLY RELEVANT DRUG-DRUG INTERACTION BETWEEN OMEPRAZOLE OR ESOMEPRAZOLE AND CLOPIDOGREL
… pump inhibitor (PPI, including omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole) with clopidogrel to decrease the risk of upper gastrointestinal bleeding. This practice was formalized for high risk patients by the American Heart Association (and others) in 2008. By 2009, …
-
Effect of CJ-12420, a novel potassium-competitive acid blocker, in gastric acid-related disease rat models
… of CJ-12420 were compared with those of esomeprazole, a representative proton pump inhibitor. In vitro enzyme assays were performed using ion-leaky vesicles containing gastric H+/K+-ATPases isolated from pigs. The in vivo efficacies of CJ-12420 were evaluated in rat models of GERD and …
-
Protonų siurblio inhibitorių suvartojimo tyrimas Lietuvoje 2022 metais /
… using the "SPSS" program. Research results: Esomeprazole is the most used PPI in Lithuania (number of e-prescriptions for esomeprazole: 34.58%), (p < 0,05). The lowest number of prescriptions issued in 2022 was for rabeprazole and lansoprazole (1.54% each). Although the population group aged …
-
The Comparative Effects of Acid Suppressants on Healthy and Neoplastic In Vitro Mast Cells
… we expect that routinely available PPIs, such as esomeprazole, might have similar effects. If so, use of PPIs in dogs with MCT disease might be of greater benefit than the use of H₂RAs. In these studies, we have shown that esomeprazole, more so than famotidine, alters healthy and neoplastic in …
-
Μελέτη της όξινης παλινδρόμησης με τη μέθοδο Bravo σε ασθενείς με νόσο από χρόνια γαστροοισοφαγική παλινδρόμηση υπό θεραπεία συντήρησης
… the efficacy of three different dosages of esomeprazole in patients receiving maintenance therapy for GERD, using the Bravo™ pH system. Methods: Patients with a previous history of erosive esophagitis A or B (LA classification) that was healed at the time of enrolment or endoscopy negative …
-
Potentiation of The Immune Checkpoint Blockade Response By Metabolic Modulation Is Predictable Using Molecular Imaging
… (ICB) as monitored using molecular imaging. Esomeprazole was found to promote tumor immunogenicity and induce tumor control when used to prime tumors one day before beginning ICB treatment. Using acido-Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (acidoCEST MRI), pHe of …
-
Synthesis, structure, and reactivity of Omeprazole and related compounds
… and the single isomer form of the drug (S)-Esomeprazole. Chapter one covers the fundamental aspects of sulfoxide chemistry, the synthesis of racemic sulfoxides, and describes various approaches to the production of chiral sulfoxides in optically pure form such as resolution, nucleophilic …
-
Identification of monoamine oxidase inhibitors using a molecular modelling approach
… = 0.761 μM for MAO-A and 5.08 μM for MAO-B), esomeprazole (IC50 = 23.2 μM for MAO-A and 48.3 μM for MAO-B) and leflunomide (IC50 = 19.1μM for MAO-A and 13.7 μM for MAO-B). The MAO inhibitory properties of caffeine and esomeprazole were further investigated. The reversibility of MAO inhibition …
-
ENANTIOSELECTIVE SYNTHESIS OF CHIRAL SULFOXIDES USING PENTANIDIUM CATALYSTS
… active compounds, for example the marketed drug Esomeprazole, and even nature products. A series of approaches have been developed to achieve the optically active sulfoxides and also make it possible for large-scale asymmetric syntheses in either stoichiometric or catalytic mode. Currently, two …
-
Detection of Pepsin in the Sputum/Saliva for Diagnosing Atypical Manifestations of Gastroesophageal Reflux Disease
… esophageal pH monitoring, and then 40 mg of esomeprazole was given twice a day for two weeks. RESULTS: The pepsin test was positive in 20 out of 40 patients with pepsin detected in 18 samples(45%) collected at the time of symptoms. Compared with 24-hr pH-metry data,the sensitivity and …
-
A longitudinal study of the usage of acid reducing medicine using a medicine claims database
… was lansoprazole during 2001 and 2002, esomeprazole during 2004 and omeprazole during 2005 and 2006. Lanzor® 30mg was the acid reducer with the highest cost from 2001 to 2005, while Pariet® 20mg took the lead in 2006. Zantac® 150mg effervescent tablets were the H2RA, with the highest …
-
Διερεύνηση της επίδρασης ενός τυπικού H2 - ανταγωνιστή της ισταμίνης (υδροχλωρική ρανιτιδίνη) στη διάμετρο της κόρης, υπό φωτοπικές και σκοτοπικές συνθήκες με το ηλεκτρονικό κορόμετρο του Colvard
… patients received the antisecretive agent esomeprazole, instead of ranitidine hydrochloride. The remaining 45 candidates formed the control group, while 62 diabetic patients were regarded as a special group that also underwent examination, through exactly the same investigative protocol. In …
-
Potential Effects of Proton Pump Inhibitors on Periodontal Disease: A Systematic Review
… pantoprazole, omeprazole, dexlansoprazole, esomeprazole) were included. Risk of bias was performed using the OHAT and QUIN assessment tools. Results: A total of 260 studies were included. Primary effects of PPIs involved alterations in bone, microbiome, enzymatic, and inflammatory systems, …
-
Burden of rheumatoid arthritis in the private health sector : medicine cost and comorbidities
… leflunomide (3.2%), etoricoxib (3.0%), naproxen/esomeprazole (1.3%), betamethasone (1.2%) and methylprednisolone (1.2%), these drugs accounting for only 34.7% of the total annual medicine cost. Rheumatoid arthritis patients with coexisting hypertension generated the highest total annual direct …